Janux Therapeutics
This role leads the immunology-focused nonclinical and clinical translational strategy for ARM programs, defining immune-monitoring strategies to deepen understanding of mechanism of action and clinical activity. The position involves leading integrated analyses of complex high-dimensional datasets, such as scRNA-seq and flow cytometry, to identify immunological signatures and mechanistic insights. The role requires cross-functional leadership to guide laboratory scientists, bioinformatics partners, and external collaborators in generating and interpreting data for program decisions.
Headquarters
San Diego, California, United States
Company Size
51-200 employees
Founded
2017
Janux Therapeutics is a biotechnology company developing precision‑engineered T cell immunotherapies. They design novel therapeutics that selectively modulate T cells to treat cancer and autoimmune diseases while minimizing systemic safety issues. Their approach focuses on targeted modulation of immune responses to improve efficacy and reduce toxicity. Janux aims to translate selective T‑cell control into safer, more effective immunotherapies.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Janux Therapeutics.
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug
1 month ago